UA-145931898-1

Bispecific Antibodies market Trends, Analysis by 2035

Comments · 106 Views

Given the recent approval of a number of bispecific antibodies and several ongoing R&D efforts focused on evaluating the potential of such candidates against various disease indications, this sector of the pharmaceutic industry has garnered significant interest of stakeholder

Roots Analysis has announced the addition of “Bispecific Antibodies Market, 2023-2035” report to its list of offerings.

 

The report features an extensive study of the current market landscape, offering an informed opinion on the likely evolution of the market for such therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

§  An executive summary of the key insights captured during our research

§  A brief introduction to bispecific antibodies, highlighting their historical background, as well as information on their structure, different types available, unique antibody formats, mechanisms of action of various drugs and their applications

§  A detailed review of the market landscape of over 220 bispecific antibodies that are either approved or being evaluated in different stages of clinical development

§  An in-depth assessment of the market landscape of over 180 bispecific antibodies that are currently being evaluated in preclinical studies

§  An insightful analysis, highlighting the contemporary market trends in the bispecific antibody therapeutics domain, through six different graphical representations

§  A detailed assessment of over 80 technology platforms being developed / used by various drug developers for the production of bispecific antibody therapeutics

§  An in-depth analysis of big pharma players engaged in this domain, featuring insightful spider web analyses and heat map analyses

§  Elaborate profiles of prominent drug developers engaged in the development of bispecific antibodies, featuring a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key members of the executive team, financial details / information (if available), drug portfolio, recent developments and an informed future outlook

§  An insightful analysis of various partnerships inked between stakeholders engaged within the bispecific antibody therapeutics domain, during the period 2016-2023

§  A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies, along with information on various contract manufacturing organizations (CMOs) and contract research organizations (CROs) engaged in this domain

§  An in-depth analysis of ongoing and planned clinical trial studies related to bispecific antibody therapeutics, which were registered till April 2023

§  A review of regulatory guidelines issued by the ICH, WHO and FDA for the development of bispecific antibodies. In addition, it provides details related to the responses of various pharmaceutical industries to the FDA guidelines

§  A review of different channels used for promoting marketed bispecific antibodies, elaborating on the various promotional strategies being adopted by developers of two approved bispecific antibodies (chosen based on their popularity in this domain), namely Blincyto™ and Hemlibra®

§  A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall market

§  A comprehensive market forecast analysis, including future sales projections of bispecific antibodies that are either marketed or under phase III of clinical development, till the year 2035, presenting a detailed market segmentation on various segments:

 

§  Therapeutic Area

§  Autoimmune Disorders

§  Genetic Disorders

§  Hematological Malignancies

§  Ophthalmic Disorders

§  Skin Cancers

§  Solid Tumors

 

§  Mechanism of Action

§  Cytokines Retargeting / Neutralization

§  Dual Ligands Blocking

§  Resistance Factors Co-targeting

§  Targeting Tumor Angiogenesis

§  T-Cell Retargeting / Activation

§  Others

 

§  Target Antigen

§  C5-Albumin

§  CD20 x CD3

§  CD3 x BCMA

§  CD3 x CD19

§  EGFR x cMET

§  EpCAM x CD3

§  Factor IXa x Factor X

§  gp100 x CD3

§  HER2 x HER2

§  PD-1 x CTLA-4

§  PD-L1 x TGFβ

§  TNF-α x HSA

§  VEGF x DLL4

§  VEGF-A x ANG2

 

§  Antibody Format

§  Asymmetric

§  Fragments

 

§  Key Players

§  Akeso Biopharma

§  Alexion

§  Amgen

§  Genmab

§  Immunocore

§  Janssen Research & Development

§  Linton Pharm

§  Merck

§  OncXerna Therapeutics

§  Pfizer

§  Roche

§  Taisho Pharmaceutical

§  Zymeworks

 

§  Key Geographical Regions

§  Asia

§  Europe

§  North America

§  Rest of the World

 

Key companies covered in the report

§  Akeso Biopharma

§  Alphamab Oncology

§  Amgen

§  Merck

§  Regeneron

§ 

Comments